Year of investment: 2011
ACS Biomarker targets discovery and validation of novel miRNA and protein-based cardiovascular biomarkers, improving diagnoses and management of cardiac diseases. ACS Biomarker licensed out exclusive rights to BG Medicine on its biomarker Galectin-3 as a prognostic indicator of congestive heart failure.
Year of investment: 2011
Nano4Imaging produces and uses medical devices and implants visible for medical interventions to monitor their function (e.g under MRI). N4I’s products MRWire and MagnaFy are used for navigation to treat cardiovascular diseases and for radiotherapy.
For more information on the company and product(s), please refer to the following video:
Year of investment: 2010
CellMade develops and commercializes cell biology products and services: human-origin primary cells, co-culture models, customized cell isolation and characterization. CellMade also invests in its own R&D program using its CellInsight platform for identification of targets and biomarkers related to inflammatory pathologies. The company has facilities in Marseille (France) and at the Chemelot Campus.
Year of investment: 2009
FABPulous develops a disposable device which allows for rapid semi-quantitative diagnostic testing in blood or plasma. The first application is for diagnosis of acute myocardial infarction, based on heart-type fatty acid binding protein (H-FABP) as a biomarker. This test is able to demonstrate, within 2-3 minutes after drawing a drop of blood by means of a finger prick, whether or not H-FABP is elevated, which is indicative of an acute myocardial infarction.
Year of investment: 2005
Basic Pharma is an advanced, independent pharmaceutical company primarily engaged in developing, licensing, manufacturing and commercialisation of pharmaceutical and biopharmaceutical products. Basic Pharma delivers a full service package to the Pharmaceutical, Biotech and Medical Device industry.